Mimicry of the Hodgkin-Associated IRAC Antigen by an Anti-Idiotype Network: Potential Use in Active Immunotherapy of Hodgkin's Lymphoma

References

• De Vita V. T. The consequences of chemotherapy of Hodgkin's disease: the 10th David A. Karnofsky Memorial Lecture. Cancer 1987; 47: 1–13
   Web of Science ®Google Scholar
• Longo D. L. The use of chemotherapy in the treatment of Hodgkin's disease. Sem-Oncol. 1990; 6: 716–735
   Google Scholar
• Pfreundschuh M., Lathan B., Loffler M., Ruffer U., Has-Enclever D., Diehl V. Workshop III: Recommendations for future clinical trials. Ann. Oncol. 1992; 3(4)101–104
   PubMedGoogle Scholar
• Herlyn D., Benden A., Kane M., Somasundaram R., Zal-Oudik J., Sperlagh M L, Marks G., Hart E., Ralph C., Wettendorff M., Mastroangelo M. Anti-Idiotype Cancer Vaccines: Pre-clinical and Clinical Studies. In vivo 1991; 5: 615–624
   PubMedGoogle Scholar
• Mittelman A., Chen Z. J., Yang H., Wong G. Y., Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-id-iotypic monoclonal antibody MK2–23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. USA 1992; 89: 466–470
   PubMed Web of Science ®Google Scholar
• Schwarting R., Stein H. Cluster report: CD 30. Leucocyte typing IV, W. Knapp, B. Dorken, W. R. Gilks, P. Rieber, R. E. Schmidt, H. Stein, A. E. G. von dem Borne. Oxford University Press, Oxford 1989; 419–422
   Google Scholar
• Hsu S. M., Ho Y. S., Hsu P. L. Expression of an activated interdigitating reticulum cell antigen (IRac) in Reed-Sternberg cells. Lab. Invest. 1986; 54: 27A
   Web of Science ®Google Scholar
• Hsu P. L., Hsu S. M. Identification of an Mr 70,000 antigen associated Reed-Sternberg cells and interdigitating reticulum cells. Cancer Res. 1990; 50: 350–375
   PubMed Web of Science ®Google Scholar
• Jerne N. Towards a network theory of the immune system. Ann. Immunol. 1974; 125: 373–389
   Google Scholar
• Kennedy R. C., Eichberg J. W., Lanford R. E., Drees-Man G. R. Anti-idiotypic antibody vaccine for type B viral Hepatitis in chimpanzees. Science 1986; 232: 220–223
   PubMed Web of Science ®Google Scholar
• Pohl C., Renner C., Schwonzen M., Schobert I., Lieben-Berg V, Jung W., Wolf J., Pfreundschuh M., Diehl V. CD30 specific Abl-Ab2-Ab3 internal image antibody network: Potential use as anti-idiotype vaccine against Hodgkin's lymphoma. Int. J. Cancer 1993; 54: 418–425
   PubMed Web of Science ®Google Scholar
• Diehl V., Kirchner H. H., Schaadt M., Fonatsch C., Stein H., Gerdes J., Boie C. Hodgkin's disease: establishment and characterization of four in vitro cell lines. J. Cancer Res. Clin. Oncol. 1984; 101: 111–117
   Web of Science ®Google Scholar
• Kearney J. F., Radbruch A., Liesegang B., Rajewski K. A. A new mouse myeloma cell line that has immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. 1979; 123: 373–389
   Google Scholar
• Behrenbeck C., Schroeder J., Da Costa L., Jung W., Schmits R., Diehl V., Gause A., Pfreundschuh M. Detection of soluble Hodgkin-associated CD30 antigen in the sera of patients with Hodgkin's lymphoma. Leucocyte typing IV, W. Knapp, et al. Oxford University Press, Oxford 1989; 419–422
   Google Scholar
• Pohl C., Renner C., Schwonzen M., Sieber M., Lorenz P., Pfreundschuh M., Diehl V. Anti-idiotype vaccine against Hodgkin's lymphoma: Induction of B- and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies. Int. J. Cancer 1992; 50: 958–967
   PubMed Web of Science ®Google Scholar
• Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• Maloney D. M., Kaminsky M., Burowsk D., Haimovich J., Levy R. Monoclonal anti-idiotype antibodies against the murine B-cell lymphoma 38C13: characterization and the use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 1985; 4: 191–197
   PubMed Web of Science ®Google Scholar
• Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of prefined specificity. Nature 1975; 256: 495–497
   PubMed Web of Science ®Google Scholar
• Raychaudhuri S., Köhler H. G., Saeki Y., Chen J. J. Potential role of anti-idiotypic antibodies in active tumor immunotherapy. Crit. Rev. Oncol. Hematol. 1989; 9: 109–117
   PubMed Web of Science ®Google Scholar
• Stein H., Mason D. Y., Gerdes J., O'Connor N., Wains-Coat J, Pallesen G., Gatter K., Falini B., Delsol G., Lemke H., Schwarting R., Lennert K. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66(4)848–858
   PubMed Web of Science ®Google Scholar
• Engert A., Martin G., Pfreundschuh M., Amlot P., Hsu S. M., Diehl V., Thorpe P. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and F (ab') fragments on solid human Hodgkin's disease tumors in mice. Cancer Res. 1990; 50: 2929–2935
   PubMed Web of Science ®Google Scholar
• Hsu S. M., Xie S. S., Hsu P. L. Cultured Reed-Sternberg cells HDLM-1 and KM-H2 can be induced to become histiocytelike cells. H-RS cells are not derived from lymphocytes. Am. J. Pathol. 1990; 137: 353–367
   PubMed Web of Science ®Google Scholar
• Nisonoff A., Lamoyi E. Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: possible application to vaccine production. Clin. Immunol. Immunopathol. 1981; 21: 397–406
   PubMedGoogle Scholar
• Gause A., Pohl C., Da Costa L., Jung W., Diehl V., Pfreundschuh M. Clinical significance of soluble CD30 antigen in the sera of patients with Hodgkin's lymphoma. Blood 1991; 77: 1983–1988
   PubMed Web of Science ®Google Scholar
• Greene M. I. Cellular and genetic basis of immune reactivity to tumor cells. Contemp. Top. Mol. Immunol. 1980; 11: 81–87
   Google Scholar
• Howie S. M., McBride W. H. Tumor specific T-helper activity can be abrogated by two distinct suppressor-cell mechanisms. Europ. J. Immunol. 1982; 12: 671–675
   PubMed Web of Science ®Google Scholar
• Köhler H., Kaveri S., Kieber-Emmons T., Morrow W. J. W., Muller S., Raychaudhuri S. Idiotope networks and nature of molecular mimicry: an overview. Meth. Enzymol. 1989; 178: 3–35
   PubMed Web of Science ®Google Scholar
• Köhler H., Kieber-Emmons T., Srinivasan S., Kaveri S., Morrow W. J. W., Miiller S., Rang C. Y., Raychau-Dhuri S. Revised immune network concepts. Clin. Immunol. Immunopathol. 1989; 52: 104–111
   PubMedGoogle Scholar
• Bhattacharya-Chatterjee M., Köhler H. G. Antiidiotype tumor vaccines. lmmunobiology of proteins and peptides, M. Z. Atassi. V. Plenum, New York 1989; 113–127
   Google Scholar
• Percy A. J., Harn D. A. Monoclonal anti-idio-typic and anti-anti-idiotypix antibodies from mice immunized with a protective monoclonal antibody against Schistosoma mansoni. J. Immunol. 1988; 140: 2760–2762
   PubMed Web of Science ®Google Scholar
• Viale G., Flamini G., Grassi F., Buffa R., Natali P. G., Pelagi M., Leoni F., Menard S., Sicardi A. G. Idiotypic replica of an anti-human tumor-associated antigen monoclonal antibody. Analysis of monoclonal Abl and Ab3 fine specificity. J. Immunol. 1989; 143: 4338–4344
   PubMed Web of Science ®Google Scholar
• Bhattacharya-Chatterjee M., Mukerjee S., Biddle W., Foon K. A., Köhler H. G. Murine monoclonal antiidiotype antibody as potential network antigen for human car-cinoembryonic antigen. J. Immunol. 1990; 145: 2758–2765
   PubMed Web of Science ®Google Scholar
• Levy R., Miller R. A. Therapy of lymphoma directed at idiotypes. J. Natl. Cancer Inst. Monogr. 1990; 10: 61–68
   PubMedGoogle Scholar